ALT Altimmune Inc

Altimmune to Host Virtual R&D Day on March 13, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025

Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA

GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time.

The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering the scientific rationale for pemvidutide in each indication, clinical data generated to-date and plans for the continued development of pemvidutide, including the upcoming topline data readout from IMPACT, the Company’s Phase 2b trial in MASH, which is expected in the second quarter of 2025.

The event will be available at and via the section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications. For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Company Contact:

Greg Weaver

Chief Financial Officer

Phone: 240-654-1450

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

Media Contact:

Danielle Cantey

Inizio Evoke, Biotech

Phone: 619-826-4657

This press release was published by a CLEAR® Verified individual.



EN
06/03/2025

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

Free Trial
ALT ALTIMMUNE INC

Altimmune Inc: 1 director

A director at Altimmune Inc maiden bought 10,000 shares at 5.200USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

03/15/25 March 15, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Host Virtual R&D Day on March 13, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025 Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering t...

March 6, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in the Leerink Global Healthcare Conference

Altimmune to Participate in the Leerink Global Healthcare Conference GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows: Conference:Leerink Global Healthcare Conference  Date/Time:Monday, March 10, 2025, at 3:40 p.m. EST The session will be webcast and can be accessed by visiting the section of the Altimmune website. About Altimmune Altimmune is a late cli...

March 3, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Result...

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to...

February 27, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry D...

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GL...

February 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch